 |
|
|
| |
A Subgroup Analysis of the Week 96 Efficacy and Safety Results Evaluating
Fostemsavir in Heavily Treatment-Experienced HIV-1 Infected Participants
in the Phase 3 BRIGHTE Study: Results From The Randomized Cohort
|
| |
| |
Reported by Jules Levin
10th IAS Conference on HIV Science (IAS 2019), 21-24 July 2019, Mexico City, Mexico
|
| |
|
|
|
|
|
